Finally, to determine if promoter methylation contributes to EHF and CDX1 silencing in CRC, we treated the poorly-differentiated HCT116 and RKO cells with the de-methylating agent 5-aza-2′-deoxycytidine (Decitabine), which significantly increased mRNA expression of both EHF and CDX1 (Fig. 7G, H). This evidence concerns the gene EHF and colorectal carcinoma.